Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Orelabrutinib in Patients With Primary Immune Thrombocytopenia (ITP)

NCT05124028 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT05124028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05124028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Orelabrutinib in Patients With Primary Immune Thrombocytopenia (ITP)
Lead sponsor
Peking University People's Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 1, 2021
Completion date
June 1, 2022
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia